Podcasts about DBS

Bobby Burton, Rod Babers, and Gerry Hamilton went all-in on today's massive showdown in Gainesville between Texas and Florida. The vibes? Confident but cautious—Texas has the edge, but the Swamp and the weather are big equalizers. Florida's Offense = Struggling Mightily QB DJ Lagway has 6 INTs already—5 on third-and-long, and most from clean pockets. Florida is 1-for-27 on third-and-7+ this season. Brutal. WR deep-ball production? Dead last in college football. Lagway is just 1-for-7 on 20+ yard throws. Texas Defensive Edge Rod and Gerry agreed: win early downs and force Florida into 3rd-and-long nightmares. Expect simulated pressures, disguised looks, and DBs feasting on predictable throws. Burke, Simmons, and Vasek off the edge vs. Florida's shaky tackles is a mismatch Texas must exploit. Special Teams X-Factor Rain and gusty winds up to 30 mph could flip this into a punter's duel. Texas WR/returner Ryan Niblett's decision-making will be crucial—field punts or let them go? A wet grass field means fewer bounces, so every choice matters. Texas kicker Mason Shipley remains perfect, while Florida's kicker has already missed three FGs this season. Score Predictions: Gerry: Texas 23–17 (tough 4Q battle, Shipley wins it late). Rod: Texas 24–10 (Longhorns' defense dominates, Florida offense never finds rhythm). Bobby: Texas 20–14 (ugly slugfest, but Texas survives). SEC Slate Talk: Vandy vs. Bama: Rod thinks Vandy keeps it close, Gerry and Bobby say Bama covers. Kentucky vs. Georgia: Straight-up talent mismatch—Dogs roll. Mississippi State vs. A&M: Panel split, but all agree it's a huge pivot game for the Aggies' playoff hopes. Miami vs. Florida State: Both Rod and Gerry love Miami's O-line/D-line combo to win in the trenches. The crew wrapped by reminding fans about the Texas tailgate in Gainesville (biggest on campus!) and all-day On Texas Football programming. Bottom line? Texas has the better team, but they need to handle the weather, the Swamp, and a desperate Gator squad. Hook ‘em!

Friend and FAMOUS MOVIE STAR, Whitney Moore joins Steve and James on a field trip to Long Beach, where they're currently making their short film, "See You Next Tuesday", Written and co-directed by Whitney, and Marques Mallare, who also pops in to say a few things about the movie, and filmmaking! And a popular, heated DEBATE from DBs past, is back and finally put to rest!Advertise on Dynamic Banter via gumball.fmJOIN the Patreon: patreon.com/dynamicbanterGET the MERCH: dynamicbanter.clothingSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jeff Howe and CJ Vogel broke down Steve Sarkisian's final pregame press conference before Texas heads to Gainesville, and the vibes are clear: the hay is in the barn, and the Horns are locked in. Emmett Mosley's Debut? Sark was coy, but all signs point to the freshman WR making his Texas debut. His perimeter blocking and length could be a huge asset, especially paired with Ryan Wingo and Parker Livingstone. Offensive Explosives via Screens: Sark emphasized the value of perimeter blocking and WR screens. Against Sam Houston State, two screens went for 65 yards—“free money,” as Jeff called it. With Mosley in the mix, Texas can bait DBs to creep up, then strike deep with Arch Manning's elite deep ball. Remember: the 83-yard screen-and-go to Livingstone earlier this year is the blueprint. Weather in Gainesville: Forecast calls for rain and wind. Sark said Texas preps weekly with “wet ball” drills—QBs, RBs, and WRs practice with soaked footballs. Wind, though, is the X-factor—field position, kickoffs, and field goals could all be impacted. Expect more 4th-down aggression if conditions hurt kicking odds. Special Teams Update: Kicker Will Stone returns for kickoffs, meaning Mason Shipley won't have to double up. That frees Shipley to focus purely on FG accuracy—critical in a weather-affected, low-scoring slugfest. RB Situation: C.J. Baxter is doubtful. Tre Wisner should be back, but not for 30 carries. Enter Jerrick Gibson, who's back home in Gainesville. Sark praised him as a short-yardage hammer, but he'll need to protect the ball after learning lessons from earlier fumbles. Christian Clark may also see touches. Sark's Bigger Picture Philosophy: Asked about the grind of SEC play, Sark made headlines saying: “People have to wrap their heads around nine and three being a good season in college football right now.” He doesn't expect anyone to run the SEC table—what matters is getting into the playoff tournament, however you have to. Bottom Line: Texas isn't chasing style points in Gainesville. With a hostile crowd, tough weather, and SEC athletes on the other sideline, Sark's golden rule applies: never, ever apologize for winning a road game in the SEC. Just get out with the W.

スカートをはいて塾に行くたび、先生の様子に違和感があった。数年後、友人と話して行動を起こした。友人と設置したスマホに映る先生の行動に、少女は思った。「やっぱり」 ※2025年9月25日に収録しました。前後編の後編です。 【関連記事】スカートの日には先生のスマホが…塾で盗撮被害、少女の違和感と決断https://www.asahi.com/articles/ASS663R0YS66PIHB008M.html?iref=omny あのとき認識できなかった性被害、20年が過ぎ　日本版DBSに思うhttps://www.asahi.com/articles/ASS3H32C0S32UTFL004.html?iref=omny 教員の性暴力、描いた漫画出版　作者が指摘する「時限爆弾」と特殊性https://www.asahi.com/articles/ASSBQ40ZGSBQULLI005M.html?iref=omny 【出演・スタッフ】MC　山下知子（デジタル企画報道部・編集委員） https://buff.ly/Hu26skk 神田大介 https://bit.ly/4k4ZKwA 音源編集　杢田光 【朝ポキ情報】アプリで記者と対話 http://t.asahi.com/won1 交流はdiscord https://bit.ly/asapoki_discord おたよりフォーム https://bit.ly/asapoki_otayori 朝ポキTV https://www.youtube.com/@asapoki_official メルマガ https://bit.ly/asapoki_newsletter 広告ご検討の企業様は http://t.asahi.com/asapokiguide 番組検索ツール https://bit.ly/asapoki_cast 最新情報はX https://bit.ly/asapoki_twitter 番組カレンダー https://bit.ly/asapki_calendar 全話あります公式サイト https://bit.ly/asapoki_lp See omnystudio.com/listener for privacy information.

Modern finance leaders have had to navigate turbulent waters over the last five to 10 years, buffeted by waves of geopolitical and macro market forces, rising economic nationalism, trade protectionism and environmental instability. Add that to the unprecedented pace of technological change, shifting consumer behaviours and a reimagined workforce. Here to give us insight on how CFOs are dealing with today's tough climate while preparing for the future is Kwee Juan Han, Group Executive and Group Head of Institutional Banking at DBS, Marie Myers, CFO at Hewlett Packard Enterprise and Andre Khor, Group CFO & Deputy CEO at Aster, part of the Chandra Asri Group.Sources: FT Resources, Deloitte, Forbes, ProtivitiThis content is paid for by DBS and is produced in partnership with the Financial Times' Commercial Department. Hosted on Acast. See acast.com/privacy for more information.

Central Connecticut's Chris Jean joins the podcast this week. The redshirt freshman defensive back talks about what it was like to get a championship ring, how the Blue Devils have started this season, and gives some advice to young DBs who want to get to the college level. The NEC's Craig D'Amico runs through the week 4 results, gives us his top three stars, and looks ahead to the week 5 slate.

The Auburn Tigers are at the Texas A&M Aggies. Texas A&M Football is undefeated and The Tigers are looking to avoid an 0-2 SEC start and are a 6.5-point underdog in College Station. Could Auburn injuries have a big impact on the outcome of this game? Mike Elko gets asked how he thinks his DBs match up against Eric Singleton and Cam Coleman Hugh Freeze shreds the special teams unit Aaron Murray previews Alabama at Georgia The Alabama Crimson Tide is on the road at The Georgia Bulldogs. Alabama Football is a 3-point underdog at Georgia Football. Kalen DeBoer's record against ranked teams is terrific but his Alabama road record is not great. Which one matters most? PLUS, Tyler's Viewing Menu presented by Michelson Laser Vision! FOLLOW TNR ON RUMBLE: https://rumble.com/c/c-7759604 FOLLOW TNR ON SPOTIFY: https://open.spotify.com/show/7zlofzLZht7dYxjNcBNpWN FOLLOW TNR ON APPLE PODCASTS: https://podcasts.apple.com/us/podcast/the-next-round/id1797862560 WEBSITE: https://nextroundlive.com/ MOBILE APP: https://apps.apple.com/us/app/the-next-round/id1580807480 SHOP THE NEXT ROUND STORE: https://nextround.store/ Like TNR on Facebook: / nextroundlive Follow TNR on Twitter: / nextroundlive Follow TNR on Instagram: / nextroundlive Follow everyone from the show on Twitter: Jim Dunaway: / jimdunaway Ryan Brown: / ryanbrownlive Lance Taylor: / thelancetaylor Scott Forester: / scottforestertv Tyler Johns: /TylerJohnsTNR Sponsor the show: sales@nextroundlive.com #SEC #Alabama #Auburn #secfootball #collegefootball #cfb #cfp #football #sports #alabamafootball #alabamabasketball #auburnbasketball #auburnfootball #rolltide #wareagle #alabamacrimsontide #auburntigers #nfl #sportsnews #footballnews Learn more about your ad choices. Visit megaphone.fm/adchoices

September is Fall Prevention month. As we age, falling—or even the fear of falling—becomes increasingly common. For people with Parkinson's, the risk is often higher due to specific changes in the body that affect balance, strength, and coordination. Almost all of us will experience a fall at some point, which is why it's so important to understand your abilities, recognize your tendencies, and keep open communication with your neurologist and care team. The good news is that there are effective ways to improve balance, manage dizziness, and build strength. Prevention truly is key. Today, I have two special guests joining me: ·       Dr. Ospina, a Movement Disorder Specialist (MDS), who explains why people with Parkinson's are more likely to face fall risks as part of the disease process—and what's happening in the body that leads to falls. She also shares strategies and treatments that can help reduce those risks. ·       A home safety expert, whose company evaluates living spaces and provides personalized recommendations to make your home safer. Their process is clinically guided, ensuring that the solutions fit your individual needs. This service is incredibly valuable for anyone looking to prevent falls at home. As we recognize Fall Prevention Month, I'd love to hear from you. Do you have a personal story about a fall, or tips you've used to reduce your ownl risk? Please share your experiences in the comments section or email at info@17branches.org.  Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches  https://www.dbsandme.com/17branches  https://measurabilities.com/ https://www.cdc.gov/falls/about/index.html    

Paroxysmal movement disorders refer to a group of highly heterogeneous disorders that present with attacks of involuntary movements without loss of consciousness. These disorders demonstrate considerable and ever-expanding genetic and clinical heterogeneity, so an accurate clinical diagnosis has key therapeutic implications. In this episode, Kait Nevel, MD, speaks with Abhimanyu Mahajan, MD, MHS, FAAN, author of the article “Paroxysmal Movement Disorders” in the Continuum® August 2025 Movement Disorders issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Mahajan is an assistant professor of neurology and rehabilitation medicine at the James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders at the University of Cincinnati in Cincinnati, Ohio. Additional Resources Read the article: Paroxysmal Movement Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Guest: @MahajanMD Full episode transcript available here Dr Jones: This is Doctor Lyell Jones, editor in chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kait Nevel. Today I'm interviewing doctor Abhi Mahajan about his article on diagnosis and management of paroxysmal movement disorders, which appears in the August 2025 Continuum issue on movement disorders. Abhi, welcome to the podcast and please introduce yourself to the audience. Dr Mahajan: Thank you, Kait. Thank you for inviting me. My name is Abhi Mahajan. I'm an assistant professor of neurology and rehabilitation medicine at the University of Cincinnati in Cincinnati, Ohio. I'm happy to be here. Dr Nevel: Wonderful. Well, I'm really excited to talk to you about your article today on this very interesting and unique set of movement disorders. So, before we get into your article a little bit more, I think just kind of the set the stage for the discussion so that we're all on the same page. Could you start us off with some definitions? What are paroxysmal movement disorders? And generally, how do we start to kind of categorize these in our minds? Dr Mahajan: So, the term paroxysmal movement disorders refers to a group of highly heterogeneous disorders. These may present with attacks of involuntary movements, commonly a combination of dystonia and chorea, or ataxia, or both. These movements are typically without loss of consciousness and may follow, may follow, so with or without known triggers. In terms of the classification, these have been classified in a number of ways. Classically, these have been classified based on the trigger. So, if the paroxysmal movement disorder follows activity, these are called kinesigenic, paroxysmal, kinesigenic dyskinesia. If they are not followed by activity, they're called non kinesigenic dyskinesia and then if they've followed prolonged activity or exercise they're called paroxysmal exercise induced dyskinesia. There's a separate but related group of protogynous movement disorders called episodic attacks here that can have their own triggers. Initially this was the classification that was said. Subsequent classifications have placed their focus on the ideology of these attacks that could be familiar or acquired and of course understanding of familiar or genetic causes of paroxysmal movement disorders keeps on expanding and so on and so forth. And more recently, response to pharmacotherapy and specific clinical features have also been introduced into the classification. Dr Nevel: Great, thank you for that. Can you share with us what you think is the most important takeaway from your article for the practicing neurologist? Dr Mahajan: Absolutely. I think it's important to recognize that everything that looks and sounds bizarre should not be dismissed as malingering. Such hyperkinetic and again in quotations, “bizarre movements”. They may appear functional to the untrained eye or the lazy eye. These movements can be diagnosed. Paroxysmal movement disorders can be diagnosed with a good clinical history and exam and may be treated with a lot of success with medications that are readily available and cheap. So, you can actually make a huge amount of difference to your patients' lives by practicing old-school neurology. Dr Nevel: That's great, thank you so much for that. I can imagine that scenario does come up where somebody is thought to have a functional neurological disorder but really has a proximal movement disorder. You mentioned that in your article, how it's important to distinguish between these two, how there can be similarities at times. Do you mind giving us a little bit more in terms of how do we differentiate between functional neurologic disorder and paroxysmal movement disorder? Dr Mahajan: So clinical differentiation of functional neurological disorder from paroxysmal movement disorders, of course it's really important as a management is completely different, but it can be quite challenging. There's certainly an overlap. So, there can be an overlap with presentation, with phenomenology. Paroxysmal nature is common to both of them. In addition, FND and PMD's may commonly share triggers, whether they are movement, physical exercise. Other triggers include emotional stimuli, even touch or auditory stimuli. What makes it even more challenging is that FND's may coexist with other neurological disorders, including paroxysmal movement disorders. However, there are certain specific phenom phenotypic differences that have been reported. So specific presentations, for example the paroxysms may look different. Each paroxysm may look different in functional neurological disorders, specific phenotypes like paroxysmal akinesia. So, these are long duration episodes with eyes closed. Certain kinds of paroxysmal hyperkinesia with ataxia and dystonia have been reported. Of course. More commonly we see PNES of paroxysmal nonepileptic spells or seizures that may be considered paroxysmal movement disorders but represent completely different etiology which is FND. Within the world of movement disorders, functional jerks may resemble propiospinal myoclonus which is a completely different entity. Overall, there are certain things that help separate functional movement disorders from paroxysmal movement disorders, such as an acute onset variable and inconsistent phenomenology. They can be suggestibility, distractibility, entrainment, the use of an EMG may show a B-potential (Bereitschaftspotential) preceding the movement in patients with FND. So, all of these cues are really helpful. Dr Nevel: Great, thanks. When you're seeing a patient who's reporting to these paroxysmal uncontrollable movements, what kind of features of their story really tips you off that this might be a proximal movement disorder? Dr Mahajan: Often these patients have been diagnosed with functional neurological disorders and they come to us. But for me, whenever the patient and or the family talk about episodic movements, I think about these. Honestly, we must be aware that there is a possibility that the movements that the patients are reporting that you may not see in clinic. Maybe there are obvious movement disorders. Specifically, there's certain clues that you should always ask for in the history, for example, ask for the age of onset, a description of movements. Patients typically have videos or families have videos. You may not be able to see them in clinic. The regularity of frequency of these movements, how long the attacks are, is there any family history of or not? On the basis of triggers, whether, as I mentioned before, do these follow exercise? Prolonged exercise? Or neither of the above? What is the presentation in between attacks, which I think is a very important clinical clue. Your examination may be limited to videos, but it's important not just to examine the video which represents the patient during an attack, but in between attacks. That is important. And of course, I suspect we'll get to the treatment, but the treatment can follow just this part, the history and physical exam. It may be refined with further testing, including genetic testing. Dr Nevel: Great. On the note of genetic testing, when you do suspect a diagnosis of paroxysmal movement disorder, what are some key points for the provider to be aware of about genetic testing? How do we go about that? I know that there are lots of different options for genetic testing and it gets complicated. What do you suggest? Dr Mahajan: Traditionally, things were a little bit easier, right, because we had a couple of genes that have been associated with the robust movement disorders. So, genetic testing included single gene testing, testing for PRRT2 followed by SLC2A. And if these were negative, you said, well, this is not a genetic ideology for paroxysmal movement disorders. Of course, with time that has changed. There's an increase in known genes and variants. There is increased genetic entropy. So, the same genetic mutation may present with many phenotypes and different genetic mutations may present with the similar phenotype. Single gene testing is not a high yield approach. Overall genetic investigations for paroxysmal movement disorders use next generation sequencing or whole exome sequence panels which allow for sequencing of multiple genes simultaneously. The reported diagnostic yield with let's say next generation sequencing is around 35 to 50 percent. Specific labs at centers have developed their own panels which may improve the yield of course. In children, microarray may be considered, especially the presentation includes epilepsy or intellectual disability because copy number variations may not be detected by a whole exome sequencing or next generation sequencing. Overall, I will tell you that I'm certainly not an expert in genetics, so whenever you're considering genetic testing, if possible, please utilize the expertise of a genetic counsellor. Families want to know, especially as an understanding of the molecular underpinnings and knowledge about associated mutations or variations keeps on expanding. We need to incorporate their expertise. A variant of unknown significance, which is quite a common result with genetic testing, may not be a variant of unknown significance next year may be reclassified as pathogenic. So, this is extremely important. Dr Nevel: Yeah. That's such a good point. Thank you. And you just mentioned that there are some genetic mutations that can lead to multiple different phenotypes. Seemingly similar phenotypes can be associated with various genetic mutations. What's our understanding of that? Do we have an understanding of that? Why there is this seeming disconnect at times between the specific genetic mutation and the phenotype? Dr Mahajan: That is a tough question to answer for all paroxysmal movement disorders because the answer may be specific to a specific mutation. I think a great example is the CACNA1A mutation. It is a common cause of episodic ataxia type 2. Depending on when the patient presents, you can have a whole gamut of clinical presentations. So, if the patient is 1 year old, the patient can present with epileptic encephalopathy. Two to 5 years, it can be benign paroxysmal torticollis of infancy. Five to 10 years, can present with learning difficulties with absence epilepsy and then of course later, greater than 10 years, with episodic ataxia (type) 2 hemiplegic migraine and then a presentation with progressive ataxia and hemiplegic migraines has also been reported. So not just episodic progressive form of ataxia has also been reported. I think overall these disorders are very rare. They are even more infrequently diagnosed than their prevalence. As such, the point that different genetic mutations present with different phenotypes, or the same genetic mutation I may present with different phenotypes could also represent this part. Understanding of the clinical presentation is really incomplete and forever growing. There's a new case report or case series every other month, which makes this a little bit challenging, but that's all the more reason for learning about them and for constant vigilance for patients who show up to our clinic. Dr Nevel: Yeah, absolutely. What is our current understanding of the associated pathophysiology of these conditions and the pathophysiology relating to the genetics? And then how does that relate to the treatment of these conditions? Dr Mahajan: So, a number of different disease mechanisms have been proposed. Traditionally, these were all thought to be ion channelopathies, but a number of different processes have been proposed now. So, depending on the genetic mutation that you talk about. So certain mutations can involve ion channels such as CACMA1A, ATP1A3. It can involve solute carriers, synaptic vesicle fusion, energy metabolism such as ECHS1, synthesis of neurotransmitters such as GCH1. So, there are multiple processes that may be involved. I think overall for the practicing clinician such as me, I think there is a greater need for us to understand the underlying genetics and associated phenotypes and the molecular mechanisms specifically because these can actually influence treatment decisions, right? So, you mentioned that specific genetic testing understanding of the underlying molecular mechanism can influence specific treatments. As an example, a patient presenting with proximal nocturnal dyskinesia with mutation in the ADCY5 gene may respond beautifully to caffeine. Other examples if you have SLC2A1, so gluc-1 (glucose transporter type 1) mutation, a ketogenic diet may work really well. If you have PDHA1 mutation that may respond to thiamine and so on and so forth. There are certain patients where paroxysmal movement disorders are highly disabling and you may consider deep brain stimulation. That's another reason why it may be important to understand genetic mutations because there is literature on response to DBS with certain mutations versus others. Helps like counselling for patients and families, and of course introduces time, effort, and money spent in additional testing. Dr Nevel: Other than genetic testing, what other diagnostic work up do you consider when you're evaluating patients with a suspected paroxysmal movement disorder? Are there specific things in the history or on exam that would prompt you to do certain testing to look for perhaps other things in your differential when you're first evaluating a patient? Dr Mahajan: In this article, I provide a flow chart that helps me assess these patients as well. I think overall the history taking and neurological exam outside of these paroxysms is really important. So, the clinical exam in between these episodic events, for example, for history, specific examples include, well, when do these paroxysms happen? Do they happen or are they precipitated with meals that might indicate that there's something to do with glucose metabolism? Do they follow exercise? So, a specific example is in Moyamoya disease, they can be limb shaking that follows exercise. So, which gives you a clue to what the etiology could be. Of course, family history is important, but again, talking about the exam in between episodes, you know, this is actually a great point because out– we've talked about genetics, we've talked about idiopathic paroxysmal movement disorders, –but a number of these disorders are because of acquired causes. Well, of course it's important because acquired causes such as autoimmune causes, so multiple sclerosis, ADEM, lupus, LGI1, all of these NMDAR, I mentioned Moyamoya disease and metabolic causes. Of course, you can consider FND as under-acquired as well. But all of these causes have very different treatments and they have very different prognosis. So, I think it's extremely important for us to look into the history with a fine comb and then examine these patients in between these episodes and keep our mind open about acquired causes as well. Dr Nevel: When you evaluate these patients, are you routinely ordering vascular imaging and autoimmune kind of serologies and things like that to evaluate for these other acquired causes or it does it really just depend on the clinical presentation of the patient? Dr Mahajan: It mostly depends on the clinical presentation. I mean, if the exam is let's say completely normal, there are no other risk factors in a thirty year old, then you know, with a normal exam, normal history, no other risk factors. I may not order an MRI of the brain. But if the patient is 55 or 60 (years) with vascular risk factors, then you have to be mindful that this could be a TIA. If the patient has let's say in the 30s and in between these episodes too has basically has a sequel of these paroxysms, then you may want to consider autoimmune. I think the understanding of paraneoplastic, even autoimmune disorders, is expanding as well. So, you know the pattern matters. So, if all of this is subacute started a few months ago, then I have a low threshold for ordering testing for autoimmune and paraneoplastic ideology is simply because it makes such a huge difference in terms of how you approach the treatment and the long-term prognosis. Dr Nevel: Yeah, absolutely. What do you find most challenging about the management of patients with paroxysmal movement disorders? And then also what is most rewarding? Dr Mahajan: I think the answer to both those questions is, is the same. The first thing is there's so much advancement in what we know and how we understand these disorders so regularly that it's really hard to keep on track. Even for this article, it took me a few months to write this article, and between the time and I started and when I ended, there were new papers to include new case reports, case series, right? So, these are rare disorders. So most of our understanding for these disorders comes from case reports and case series, and it's in a constant state of advancement. I think that is the most challenging part, but it's also the most interesting part as well. I think the challenging and interesting part is the heterogeneity of presentation as well. These can involve just one part of your body, your entire body can present with paroxysmal events, with multiple different phenomenologies and they might change over time. So overall, it's highly rewarding to diagnose such patients in clinic. As I said before, you can make a sizeable difference with the medication which is usually inexpensive, which is obviously a great point to mention these days in our health system. But with anti-seizure drugs, you can put the right diagnosis, you can make a huge difference. I just wanted to make a point that this is not minimizing in any way the validity or the importance of diagnosing patients with functional neurological disorders correctly. Both of them are as organic. The importance is the treatment is completely different. So, if you're diagnosing somebody with FND and they do have FND and they get cognitive behavioral therapy and they get better, that's fantastic. But if somebody has paroxysmal movement disorders and they undergo cognitive behavioral therapy and they're not doing well, that doesn't help anybody. Dr Nevel: One hundred percent. As providers, obviously we all want to help our patients and having the correct diagnosis, you know, is the first step. What is most interesting to you about paroxysmal movement disorders? Dr Mahajan: So outside of the above, there are some unanswered questions that I find very interesting. Specifically, the overlap with epilepsy is very interesting, including shared genes, the episodic nature, presence of triggers, therapeutic response to anti-seizure drugs. All of this I think deserves further study. In the clinic, you may find that epilepsy and prognosis for movement disorders may occur in the same individual or in a family. Episodic ataxia has been associated with seizures. Traditionally this dichotomy of an ictal focus. If it's cortical then it's epilepsy, if it's subcortical then it's prognosis for movement disorders. This is thought to be overly simplistic. There can be co-occurrence of seizures and paroxysmal movement disorders in the same patient and that has led to this continuum between these two that has been proposed. This is something that needs to be looked into in more detail. Our colleagues in Epilepsy may scoff this, but there's concept of basal ganglia epilepsy manifesting as paroxysmal movement disorders was proposed in the past. And there was this case report that was published out of Italy where there was ictal discharge from the supplementary sensory motor cortex with a concomitant discharge from the ipsilateral coordinate nucleus in a patient with paroxysmal kinesigenic cardioarthidosis. So again, you know, basal ganglia epilepsy, no matter what you call it, the idea is that there is a clear overlap between these two conditions. And I think that is fascinating. Dr Nevel: Really interesting stuff. Well, thank you so much for chatting with me today. Dr Mahajan: Thank you, Kait. And thank you to the Continuum for inviting me to write this article and for this chance to speak about it. I'm excited about how it turned out, and I hope readers enjoy it as well. Dr Nevel: Today again, I've been interviewing doctor Abhi Mahajan about his article on diagnosis and management of paroxysmal movement disorders, which appears in the August 2025 Continuum issue on movement disorders. I encourage all of our listeners to be sure to check out the Continuum Audio episodes from this and other issues. As always, please read the Continuum articles where you can find a lot more information than what we were able to cover in our discussion today. And thank you for our listeners for joining today. And thank you, Abhi, so much for sharing your knowledge with us today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Ohio State hits the road for their Big Ten opener at Washington, and today we're breaking down how the Buckeye offense matches up against the Huskies defense. Can Julian Sayin handle his first hostile road start? Will Bo Jackson and the deep RB room crack Washington's top-10 run defense? And how will Jeremiah Smith and Brandon Inniss exploit a shaky Husky secondary? We dive into: Ryan Walters' defensive scheme at Washington Why OSU's offensive line could control the trenches Red zone execution and finishing drives The matchups to watch: WRs vs DBs, RBs vs front seven Don't miss this full preview of Ohio State's offense vs Washington's defense in a game that could shape the Big Ten race. Tuesday, September 23, 2025 Subscribe to the Podcast

Crypto News: Gary Gensler joined CNBC today and spread FUD about crypto. DBS, Franklin Templeton and Ripple will offer tokenized trading and lending services on the XRP Ledger to attract institutional investors. Grayscale prepares to stake Ether holdings amid shifting SEC stance.Show Sponsor -

Singapore's Straits Times Index (STI) opened lower in early trade, as investors reacted to caution stemming from the US Federal Reserve’s first interest rate cut since December 2024. Among key stocks, DBS, OCBC and UOB fell between 0.6-1%. This comes as current rate pressures and sector rotation weighed on the counters. Meanwhile, Asia-Pacific markets traded mixed, with Japan’s benchmark Nikkei index rose around 1% to a fresh record in early trade. On Market View, Willie Keng speaks to David Chow, Director of Azure Capital, to find out more about the latest market developments. See omnystudio.com/listener for privacy information.

As we continue our Thailand25 series, many of you will remember Rey from Hong Kong and how God used him to see movement among Filipina maids. In this episode, Rey continues to share the journey of seeing movement in and from Hong Kong. In July 2022, Rey pioneered Discovery Obedience Bible Studies (DOBS) in Hong Kong parks with Pilipino maids. What began as one small step of faith has now grown into multiplying disciple-making communities (DMCs) in Hong Kong, Macau, the Philippines, and even Japan. Rey's obedience to the Holy Spirit has opened the door to multiplication down to third and fourth generations of disciples. His passion is clear: “We are not in the business of making believers but disciples.” You'll be encouraged as Rey explains how God is using simple obedience, a clear disciple-making vision, and a commitment to multiplication to bring transformation from Hong Kong to the nations. Highlights from Rey's Journey Early Exposure to Movements Since 2016, Rey was exposed to disciple-making movements through experiences in Israel, India, and Myanmar, which grew into a deep passion and became the focus of his Master's thesis in Hong Kong. From Pastor to Movement Pioneer His church in Hong Kong adopted DMM principles—but only as a growth strategy, not a true disciple-making movement. The spark eventually faded. 2022: Rey resigned from traditional church ministry, rejecting offers from large churches.  During quarantine, while fasting and praying, God's answer surprised him: not to join another church, but to start doing DMM himself. July 2, 2022: Rey launched the first DOBS group in a Hong Kong park. Multiplication Across Nations Hong Kong: Now 110 active disciples. 3 DMCs (up to 4th generation). 201 baptisms over the last three years—monthly beach baptisms with new believers. 20 women in training to become “DMM pastors,” preparing to return to the Philippines. Macau: 1 group, 8 active disciples, 3 disciple-makers. Philippines: Communities in the north, central, and the Muslim south (Mindanao). Over 100 active disciples in multiple generations. Japan (Yokosuka, near Tokyo): Filipina women reaching out to bar owners and families. Baptisms and new groups forming into a multiplying community. Disciple-Making Process Rey uses DOBS (Discovery Obedience Bible Studies): Discover, Obey, Bible, Share. He has developed different levels of scripture sets: Seekers – discovering Jesus. Disciples – going deeper. Leaders – training for multiplication. Vision & Tools Rey always gives the vision upfront: everyone is called to be a disciple-maker. He even draws people a simple path: Seeker → Believer → Disciple → Disciple-Maker → Leader. Anchors everything in key Scriptures: Matthew 28:18-20 (Great Commission), Matthew 22:36-39 (Great Commandment), Acts 1:8 (Need for Holy Spirit to be witnesses) and 2 Timothy 2:2 (Multiplication of disciples). DBS format follows the 4Ws: Worship Watch (share stresses) Word (Head, Heart, Hands) Work (commitments & sharing). Why Listen? Rey's story is one of courage, obedience, and multiplication. From humble beginnings in a park in Hong Kong to movements multiplying in the Philippines and Japan, Rey's testimony challenges us to rethink church, embrace disciple-making, and trust God's Spirit to lead.

Can Penn State's offense keep up with its dominant defense? This week, Hack and Cabinda go in-depth on what's working, what's not, and what to expect from the Nittany Lions this season. From the stellar defensive performances under Jim Knowles to questions surrounding Drew Allar and the offensive play-calling, we dive into the big picture and discuss the keys to success for Penn State football moving forward.Here's what to expect:- How the defense continues to dominate with explosive turnovers and lockdown DBs.- The offense's struggle to establish a consistent identity and push the ball vertically.- Drew Allar's growth, strengths, and the question of his ceiling as a QB.- The balance between Nick Singleton and Kaytron Allen in the run game.- Broader college football trends, NIL's impact, and the changing nature of team chemistry.- What Penn State needs to refine during the bye week to prepare for the season's biggest tests.FOLLOW STATE MEDIA HERE:► TWITTER | ⁠https://twitter.com/StateMediaPSU⁠► TIKTOK | ⁠https://www.tiktok.com/@statemediapsu⁠► INSTAGRAM | ⁠https://www.instagram.com/statemediapsu/⁠► YOUTUBE | ⁠https://www.youtube.com/@StateMediaPSU?sub_confirmation=1⁠► FACEBOOK | https://www.facebook.com/profile.php?id=61558183472272CHAPTERS:00:00 - Intro01:14 - Villanova Recap08:49 - Defense Strategies14:35 - Defensive Analysis16:09 - Offensive Performance24:16 - Running Back Evaluation28:43 - Bye Week Strategies37:09 - Drew's Mechanics37:27 - Arch Manning39:34 - Young Players'41:36 - College Football Roundup#collegefootball #nfl #cfb #pennstate #weare #happyvalley #football #sunday #saturday

Ty Law joins with his reaction to the win, advice for young DBs and of course some donations to the swear jar

I've been eager to share with all of you in podcast land some important information and history about what I believe is one of the key drivers in helping fulfill the Michael J. Fox Foundation's mission to cure Parkinson's disease. The Parkinson's Progression Markers Initiative (PPMI), launched in 2010, is a groundbreaking study involving people both with and without Parkinson's. It gathers data over time to help researchers better understand how Parkinson's starts, how it progresses, and — most importantly — how to stop it. Sound important? It absolutely is. And it's still going strong, continually recruiting new participants to join its large and growing community of volunteers. The more data we collect through PPMI, the faster we can accelerate the path to a cure. Maggie Kuhl and Alyssa O'Grady are at the heart of this effort — overseeing the data, bringing in new participants, and tracking the initiative's progress every step of the way. Listen to what the experts say about how you can contribute to the solution to the Parkinson's puzzle. Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   https://www.michaeljfox.org/ppmi https://www.ppmi-info.org/    

In this episode we do only phone calls! We get someone who has crazy DBS probably the biggest of the year, then a psychic told her she should contact her ex then we talk to a DBS survivor! Buy Tickets to  Theme Speed Dating in LONG BEACH October 12th!https://www.eventbrite.com/e/1665854448499?aff=oddtdtcreatorhttps://www.instagram.com/themespeeddating/ Buy Merch Here!https://www.inlandentertainment.com Call Us To Be On The Show!https://docs.google.com/forms/d/e/1FAIpQLSdV8WNMg69TLL4nYttVh_mKAoLRYzRtnCT226InJqh3ixQR5g/viewform Follow Us!https://linktr.ee/buenobuenopdc Saul V GomezInstagram -  https://www.instagram.com/saulvgomez/Twitter - https://twitter.com/Saulvgomez_Tik Tok - https://www.tiktok.com/@saulvgomez Hans EsquivelInstagram - https://www.instagram.com/hans_esquivel/Tik Tok - https://www.tiktok.com/@hanss444 RexxInstagram - https://www.instagram.com/rexxb/Twitter - https://twitter.com/rexxgodbTik Tok - https://www.tiktok.com/@rexx.b1 Topics00:00:00 - Intro00:02:50 - Speed Dating Theme announced!00:07:40 - Biggest DBS of the year00:19:40 - Psychic told me to call my ex00:32:11 - A DBS survivor00:59:00 - Calling our biggest patron supporter01:20:00 - Patreon Shout outs

Chang She is Co-Founder & CEO of LanceDB, the multimodal lakehouse platform. Their open source data format lance has over 5K stars on GitHub and is a modern columnar data format for ML and LLMs implemented in Rust.LanceDB has raised $41M from investors including Theory Ventures, CRV, and Essence VC. In this episode, we dig into:Early focus: autonomous vehicles; solved real-time analysis limits with Lance format → 9,000% performance gain.Multi-modal AI taking off (vision, audio, text); Midjourney & Runway as pioneers; audio now a major category.How they built trust through open source.Integrated workflows (data prep + search + embedding) going beyond vector DBs; education needed to show full value.Cloud/serverless launch in 2023–24 enabled seamless local-to-production use.Future bets: audio infra, robotics, spatial reasoning; vector DBs risk irrelevance if they don't evolve.

Tune in to this episode of the Security Token Show where this week Herwig Konings and Kyle Sonlin cover the industry leading headlines and market movements, including Wyoming issuing their own stablecoin, DBS expanding to non-bank clients, and DigiFT raising $25M, tokenized indices coming onchain, and more RWA news   Company of the Week - Herwig: Avalanche Company of the Week - Kyle: Fanable   Market Movements: Wyoming is First State to Launch Stablecoin: Frontier Stable Token (FRNT): https://www.coindesk.com/business/2025/08/19/wyoming-state-debuts-u-s-dollar-stablecoin-on-seven-blockchains Anthony Scaramucci's SkyBridge Capital to Tokenize $300M Worth of 2 Funds on Avalanche via Apex Group's Digital 3.0 Platform: https://tokeny.com/skybridge-capital-partners-with-tokeny-to-tokenize-300min-hedge-funds-on-avalanche?hss_channel=lcp-4874605 REtokens Introduces Their Broker-Dealer/ATS: REtokens Capital: https://retokens.com/announcing-retokens-capital-llc-broker-dealer-with-new-secondary-marketplace/ S&P Dow Jones Indices to Tokenize Index Products: https://www.bitget.com/news/detail/12560604915409 Centrifuge's deRWAs Go Live on Base with Tokenized Janus Henderson CLOs: https://crypto.news/centrifuge-launches-tokenized-real-world-assets-on-evm-platforms/ Epic Chain is Getting Into RWAs Through XRP-Based Platform: https://www.livebitcoinnews.com/epic-chain-launches-xrp-based-rwa-platform-to-revolutionize-finance/   Companies in the Token Debrief Include: DBS, ADDX, DigiFT, HydraX, Bitget, Swarm, Hedera, SBI, Bowmore, Avalanche, Valereum/ VLRM Markets, ZIGChain, DigiShares, Zoth, Haven1, Stellar Development Foundation, Archax, RealEstate.Exchange, FraXion, The Legacy, FIS ==== TokenizeThis 2025 Conference Review: https://docsend.com/v/k8bn7/tt25 STM Predicts $30-50T in RWAs by 2030: https://docsend.com/view/7jx2nsjq6dsun2b9 More STM.co Reports: https://reports.stm.co/ Join the RWA Foundation and Read the Whitepaper: RWAF.xyz Learn More About WALLY DAO: WallyDAO.xyz ==== ⏰ TABLE OF CONTENTS ⏰ 0:00 Introduction 0:16 Welcome 1:06 Market Movements 24:10 RWA Foundation Updates 26:24 Token Debrief 38:39 Companies of The Week

Is UK's O-line ready for prime time? Can the DBs hold it down while the front seven gels? Plus thoughts on analytics, polls and more with our guest Steven Willis of Locked On Ole Miss. #GoBigBlue https://x.com/BleavInKentucky Follow and subscribe!

Cole was back in the press box but it was his first time there for The Cats' Pause. Can Kroger Field be a tough place to play for Austin Simmons? Will UK's DBs be ready for the talented Ole Miss WRs? Steven Willis of Locked On Ole Miss stopped by to talk about that and more in part one of our conversation. Follow and subscribe!

The two biggest games in the nation are The Texas Longhorns at the Ohio State Buckeyes and the LSU Tigers at The Clemson Tigers. For Texas Football, they are playing for the first time ever as the preseason #1 team in the nation and are a 2-point road underdog. Ohio State Football is coming off winning the national championship last season. These are two of the favorites to win it all this season as well. Arch Manning's moment has arrived, what are reasonable expecations. The LSU Tigers are 4-point road underdogs at the Clemson Tigers. LSU Football feels like they are in a “National Championship of Bust” situation and Clemson Football is a very popular pick to win it this season, as well. Is this the time LSU Football breaks out of their season opening slump? LSU Football will be down one of their DBs in the first half. Transfer safety A.J. Haulcy will not be on the field early due to a first half suspension that dates back to his fight at the end of last season's BYU-Houston game when Haulcy was a member of the Cougars. Do you believe head coach Brian Kelly just found out this week about the suspension? Micah Parsons traded PLUS, LT's Trash presented by Bud Light! FOLLOW TNR ON RUMBLE: https://rumble.com/c/c-7759604‬ ‭FOLLOW TNR ON SPOTIFY: https://open.spotify.com/show/7zlofzL... ‭FOLLOW TNR ON APPLE PODCASTS: https://podcasts.apple.com/us/podcast... ‭WEBSITE: https://nextroundlive.com/‬ ‭MOBILE APP: https://nextroundlive.com/the-ne....‬ ‭SHOP THE NEXT ROUND STORE: https://nextround.store/‬ ‭Like TNR on Facebook: / nextroundlive‬ ‭ Follow TNR on X: / nextroundlive‬ Follow TNR on Instagram: / nextroundlive‬ ‭Follow everyone from the show on X:‬ ‭ Jim Dunaway: / jimdunaway‬ ‭ Ryan Brown: / ryanbrownlive‬ ‭ Lance Taylor: / thelancetaylor‬ ‭ Scott Forester: / scottforestertv‬ ‭ Tyler Johns: /TylerJohnsTNR‬ ‭ Sponsor the show: sales@nextroundlive.com‬ Learn more about your ad choices. Visit megaphone.fm/adchoices

Who holds the crown as Singapore’s most valuable company — DBS or Sea Limited? Hosted by Michelle Martin with Ryan Huang, we dive into the rivalry between banking and e-commerce giants. We unpack the Trump administration’s bold move with Intel and what it could mean for defense players like Lockheed Martin, Boeing, RTX, and Northrop Grumman. The Fed, tax moves, and tech giants also come under fire as Trump reshapes market dynamics. In our Up or Down segment, we size up Keppel, Seatrium, Haidilao, Maybank, and Signet Jewelers. Plus, the STI’s movers like SGX and SingTel, and our Last Word on Cadillac’s Formula 1 debut.See omnystudio.com/listener for privacy information.

In this episode of the All Things Sustainable podcast, we're talking to Helge Muenkel, Group Chief Sustainability Officer at Singapore's biggest bank, DBS.  The interview is the latest installment in our CSO Insights series, where we hear from Chief Sustainability Officers around the world about how they're navigating the evolving sustainability landscape.  "Big picture on climate action very specifically, the train has really left the station," Helge says of the bank's large corporate clients. "More and more customers are really seeing the transformation that is happening in our economies as a business imperative and are embracing it."  Helge explains how DBS integrates environmental and social factors into its sustainability strategy. He says climate financing continues to present big financing risks and opportunities, and points to an increasing focus on scaling blended finance.  Helge tells us that nature is also becoming an increasing focus for the bank — which echoes what we've heard from other sustainability leaders at Southeast Asian financial institutions in recent episodes. Listen to our interview with big Singapore-based bank UOB here: CSO Insights: How sustainability pullback is playing out in Southeast Asia  Listen to our interview with big Malaysia-based bank CIMB here: CSO Insights: How a big Malaysian bank balances climate, nature, human rights and economic inclusion  Listen to our interview with big Malaysian pension fund EPF here: Why one of Southeast Asia's largest pension funds is ‘doubling down' on sustainability  Hear our coverage of London Climate Action Week here: How these key summer events set the scene for COP30 in Brazil  Listen to our podcast episode: How sustainability professionals are weathering challenging times  Listen to our podcast episode where Aniket Shah, Managing Director and Global Head of the Sustainability and Transition Strategy team at Jefferies Group, explains why financial decision-makers need "data, not vibes" to drive their sustainability strategies: Connecting the dots between climate science and financial decisions  Read research from S&P Global Sustainable1 into corporate nature commitments here: Ahead of COP16, corporate nature commitments remain rare  The All Things Sustainable podcast from S&P Global will be an official media partner of The Nest Climate Campus during Climate Week NYC. Register free to attend here. This piece was published by S&P Global Sustainable1 and not by S&P Global Ratings, which is a separately managed division of S&P Global.   Copyright ©2025 by S&P Global DISCLAIMER By accessing this Podcast, I acknowledge that S&P GLOBAL makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast. The information, opinions, and recommendations presented in this Podcast are for general information only and any reliance on the information provided in this Podcast is done at your own risk. Any unauthorized use, facilitation or encouragement of a third party's unauthorized use (including without limitation copy, distribution, transmission or modification, use as part of generative artificial intelligence or for training any artificial intelligence models) of this Podcast or any related information is not permitted without S&P Global's prior consent subject to appropriate licensing and shall be deemed an infringement, violation, breach or contravention of the rights of S&P Global or any applicable third-party (including any copyright, trademark, patent, rights of privacy or publicity or any other proprietary rights). This Podcast should not be considered professional advice. Unless specifically stated otherwise, S&P GLOBAL does not endorse, approve, recommend, or certify any information, product, process, service, or organization presented or mentioned in this Podcast, and information from this Podcast should not be referenced in any way to imply such approval or endorsement. The third party materials or content of any third party site referenced in this Podcast do not necessarily reflect the opinions, standards or policies of S&P GLOBAL. S&P GLOBAL assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this Podcast or the compliance with applicable laws of such materials and/or links referenced herein. Moreover, S&P GLOBAL makes no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that manifest contaminating or destructive properties.     S&P GLOBAL EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL'S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST.

How does an investor make sense of market signals? DBS crosses the $50 milestone — but should investors chase momentum or take profit? Hosted by Michelle Martin, this episode features Willie Keng, Founder of Dividend Titan, who explains why he isn’t buying DBS at these levels and why he sold out of ST Engineering despite its $31 billion order book. We dive deep into Singapore’s three big banks — DBS, OCBC, and UOB — and ask which one is best positioned for growth today. PropNex’s record profits also come under the spotlight: what do they reveal about the resilience of Singapore’s property market? ST Engineering’s stellar performance raises the valuation dilemma — when is “too high” really too high?See omnystudio.com/listener for privacy information.

Listening to personal Parkinson's stories offers valuable insights for everyone. In this episode, we interview Greg Ritscher, who responded to his diagnosis with determination shaped by his business and personal experiences. Greg also shares a notable DBS story. His journey highlights motivation, positivity, community support, and advocacy. Enjoy our inspiring conversation with Greg.  https://gregritscher.com/ https://www.dbsandme.com/17branches Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

Dominate your 2025 fantasy football league with our essential guide. - Expert IDP Advice: 2025 Fantasy Football IDP & WK1 Start/Sit Prep! We break down offensive skill players, providing in-depth analysis of ADP trends to pinpoint sleepers, breakouts, and potential busts.

To help us sort through the signal and find the noise this preseason, we had to call in a big gun. Jon Macri returns to the show to help Josh, Adam, and Bobby make sense of all the IDP developments from training camp and two weeks of preseason games. We've got linebackers (LB2 options, exciting rookies, and stinky ol' vets), players wanting new deals, and DBs whose usage might not be what we think. All that and more on a jam-packed episode of The IDP Show.Subscribe to our YouTube channel for our other shows, The IDP After Show and All IDP.If you'd like to support the show, you can do so for just $5/month over at ⁠theIDPshow.com⁠. We've got some premium features for paid supporters that we know you'll enjoy. Follow us on Twitter ⁠@theidpshow⁠. Thanks for listening!

In this episode of Bleav in Chargers, Matt 'Money' Smith and Lorenzo Neal  discuss the Chargers' preseason performance, roster battles, injury updates, and expectations as the team prepares for their final preseason game against the San Francisco 49ers. Major talking points include offensive line issues, running back depth, Trey Lance's progression, wide receiver competition, and tight positional battles on defense. They take questions on the 53-man roster, special teams, and how the coaching staff is maximizing player potential. 00:00:17]  team's preseason so far, and looking ahead to the matchup at Levi's Stadium. [00:01:57] Discussion of potential starters' playtime, concern over preseason injuries (e.g., Quentin's concussion), and depth chart implications. [00:03:32] Evaluation of offensive line combinations, struggles in recent games, and the effect on the run game. [00:08:09] Analysis of running back injuries and battles, tight end roles, and Tucker Fisk's importance to the roster. [00:12:56] Deep dive into who makes the team, especially in the backfield and wide receiver positions. [00:16:14] Trey Lance's impact as backup QB, discussion on if he brings competition to Herbert, and the value of strong QB2. [00:21:33] How the coaching staff is approaching player development and the "next man up" philosophy. [00:25:04] Noting standout performances (like Trey Harris), changing dynamics in the WR room, and what to expect from the Chargers' air attack. [00:30:07] Uncertainty and competition among DBs, potential cuts, and the importance of special teams. [00:38:06] Marlo Wax's production, comparison to other backers, and tough cut-down decisions. [00:44:15] Use of IR/PUP to stash players, and approach to keeping key special teamers. [00:45:52] Rapid responses to fan comments, evaluation of key rookies, and final thoughts ahead of cutdown.

UOL’s stock is on fire—up nearly 40% this year—can the rally last? Analysts from CGS International, Citi, and DBS say yes, pointing to smart land buys and blockbuster project launches. Meanwhile, Wall Street cools as AI heavyweights like Nvidia and Palantir stumble. In today’s UP or DOWN, we size up Home Depot, Viking Therapeutics, Xiaomi, and iFast. The Straits Times Index regains the 4,200 level with Jardine Matheson in the lead, while ST Engineering lags. From Singapore property giants to global market movers, we connect the dots for investors. Hosted by Michelle Martin.See omnystudio.com/listener for privacy information.

Do you want to hear insights from one of the most innovative banks in Singapore? In this episode, Evy Theunis, the Head of Digital Assets, Institutional Banking Group at DBS Bank explains to Chengyi Ong (Head of Policy (APAC), Chainalysis) about the thriving presence of digital asset firms running their businesses out of Singapore Evy also shares how DBS bank has made groundbreaking strides in digital assets including many strategic initiatives such as launching their own digital asset exchange, while emphasizing the importance of regulatory frameworks and technological advancement as pivotal factors in DBS's foray into digital assets. Evy and Chengyi also marvel over the evolution and maturity of the digital assets sector and dissect DBS Bank's top-down approach to crypto trading, digital payments and the tokenization of traditional financial markets. Minute-by-minute episode breakdown 2 | Evy's Journey to DBS and Digital Assets 5 | Challenges and Opportunities in Digital Assets for a Bank 9 | DBS's Focus on Digital Assets Strategy  11 | DBS's Innovation and Role in Digital Asset Financial Products 15 | Key Components for Future Financial Infrastructure 19 | Increase Demand for Digital Assets by High Net Worth Customers 22 | Singapore as a Hub for Crypto Businesses and Regional Expansion 24 | The Monetary Authority of Singapore and Their Digital Asset Impact 27 | DBS's Future in Digital Assets   Related resources Check out more resources provided by Chainalysis that perfectly complement this episode of the Public Key. Website: DBS Treasures: Asia's Global Wealth Gateway Article: DBS Treasures: Trade crypto seamlessly on digibank Announcement: DBS Digital Exchange: Access fully integrated platform to tokenise, trade and custody of digital assets Article: MAS Clarifies Regulatory Regime for Digital Token Service Providers Blog: The President's Working Group (PWG) Report on Digital Asset Markets Makes One Thing Clear: We Will Build The Future of Crypto Together Blog: Chainalysis POV: What the GENIUS and CLARITY Act Bills Really Mean for Crypto Compliance Blog: Following the Bitcoin Trail: The IntelBroker Takedown YouTube: Chainalysis YouTube page Twitter: Chainalysis Twitter: Building trust in blockchain Speakers on today's episode Chengyi Ong (Head of Policy (APAC), Chainalysis) Evy Theunis (Head of Digital Assets, Institutional Banking Group, DBS Bank) This website may contain links to third-party sites that are not under the control of Chainalysis, Inc. or its affiliates (collectively “Chainalysis”). Access to such information does not imply association with, endorsement of, approval of, or recommendation by Chainalysis of the site or its operators, and Chainalysis is not responsible for the products, services, or other content hosted therein. Our podcasts are for informational purposes only, and are not intended to provide legal, tax, financial, or investment advice. Listeners should consult their own advisors before making these types of decisions. Chainalysis has no responsibility or liability for any decision made or any other acts or omissions in connection with your use of this material. Chainalysis does not guarantee or warrant the accuracy, completeness, timeliness, suitability or validity of the information in any particular podcast and will not be responsible for any claim attributable to errors, omissions, or other inaccuracies of any part of such material.  Unless stated otherwise, reference to any specific product or entity does not constitute an endorsement or recommendation by Chainalysis. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Chainalysis employees are those of the employees and do not necessarily reflect the views of the company.   

Post-Gazette insiders Gerry Dulac and Ray Fittipaldo recap the Steelers' joint practice with the Tampa Bay Buccaneers at Acrisure Stadium. The explain how key matchups including Jalen Ramsey vs. Mike Evans and Zach Frazier vs. Vita Vea provided the big highlights for the day; why this practice may be the most work Aaron Rodgers gets against another team in the NFL preseason; Kaleb Johnson's need to improve in pass protection if he hopes to challenge for playing time in the backfield with Jaylen Warren and Kenneth Gainwell; Baker Mayfield's stern test for DBs including Ramsey, Joey Porter Jr. and Darius Slay Jr.; and the continued excellence of defensive rookies Derrick Harmon and Yahya Black.

Essential tremor is the most common movement disorder, although it is often misdiagnosed. A careful history and clinical examination for other neurologic findings, such as bradykinesia, dystonia, or evidence of peripheral neuropathy, can reveal potential alternative etiologies. Knowledge about epidemiology and associated health outcomes is important for counseling and monitoring for physical impairment and disability. In this episode, Lyell Jones, MD, FAAN, speaks with Ludy C. Shih, MD, MMSc, FAAN, author of the article “Essential Tremor” in the Continuum® August 2025 Movement Disorders issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Shih is clinical director of the Parkinson's Disease and Movement Disorders Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Additional Resources Read the article: Essential Tremor Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @ludyshihmd Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Ludy Shih, who recently authored an article on essential tremor for our latest issue of Continuum on movement disorders. Dr Shih is an associate professor of neurology at Harvard Medical School and the clinical director of the Parkinson's Disease and Movement Disorder Center at Beth Israel Deaconess Medical Center in Boston. Dr Shih, welcome, and thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Shih: Thank you, Dr Jones, for having me. It's a real pleasure to be here on the podcast with you. I'm a neurologist, I trained in movement disorders fellowship, and I currently see patients and conduct clinical research. We offer a variety of treatments and diagnostic tests for our patients with movement disorders. And I have developed this interest, a clinical research interest in essential tremor. Dr Jones: And so, as an expert in essential tremor, the perfect person to write such a really spectacular article. And I can't wait for our listeners to hear more about it and our subscribers to read it. And let's get right to it. If you had, Dr Shih, a single most important message for our listeners about caring for patients with essential tremor, what would that message be? Dr Shih: Yeah, I think the takeaway that I've learned over the years is that people with essential tremor do develop quite a few other symptoms. And although we propose that essential tremor is this pure tremor disorder, they can experience a lot of different comorbidities. Now, there is some debate as to whether that is expected for essential tremor or is this some part of another syndrome, which we may talk about later in the interview. But the fact of the matter is, it's not a benign condition and people do experience some disability from it. Dr Jones: And I think that speaks to how the name of this disorder has evolved over time. right? You point out in your article, it used to be called benign essential tremor or benign familial tremor. But it's really not so straightforward as it. And fairly frequently these symptoms, the patient's tremor, can be functionally limiting, correct? Dr Shih: That is correct. In fact, the reason I probably started getting interested in essential tremor was because our center had been doing a lot of deep brain stimulation for essential tremor, which is remarkably effective, especially for tremor that reaches an amplitude that really no oral medication is going to satisfyingly treat. And if you have enough upper limb disability from this very large-amplitude tremor, a surgical option may make a lot of sense for a lot of patients. And yet, how did they get to that point? Do they continue to progress? These were the sort of interesting questions that got raised in my mind as I started to treat these folks. Dr Jones: We'll come back to treatment in just a minute here, because there are many options, and it sounds like the options are expanding. To start with the diagnosis- I mean, this is an extraordinarily common disorder. As you point out, it is the most common movement disorder in the US and maybe the world, and yet it seems to be underrecognized and frequently misdiagnosed. Why do you think that is? Dr Shih: Great question. It's been pretty consistent, with several case series over the decades showing a fairly high rate of quote/unquote “misdiagnosis.” And I think it speaks to two things, probably. One is that once someone sees a postural and kinetic tremor of the arms, immediately they think of essential tremor because it is quite common. But there's a whole host of things that it could actually be. And the biggest one that we also have to factor in is also the heterogeneity of the presentation of Parkinson's disease. Many people, and I think increasingly now these days, can present with not a whole lot of the other symptoms, but may present with an atypical tremor. And it becomes actually a little hard to sort out, well, do they have enough of these other symptoms for me to suspect Parkinson's, or is the nature of their tremor suspicious enough that it would just be so unusual that this stays essential tremor and doesn't eventually develop into Parkinson's disease? And I think those are the questions that we all still grapple with from time to time in some of our clinics. Dr Jones: Probably some other things related to it with, you know, our understanding of the pathophysiology and the availability of tests. And I do want to come back to those questions here in just a minute, but, you know, just the nomenclature of this disorder… I think our clinical listeners are familiar with our tendency in medicine to use words like essential or idiopathic to describe disorders or phenomena where we don't understand the precise underlying mechanism. When I'm working with our trainees, I call these “job-security terms” because it sounds less humbling than “you have a tremor and we don't know what causes it,” right? So, your article does a really nice job outlining the absence of a clear monogenic or Mendelian mechanism for essential tremor. Do you think we'll ever have a eureka moment in neurology for this disorder and maybe give it a different name? Dr Shih: It's a great question. I think as we're learning with a lot of our neurologic diseases---and including, I would even say, Parkinson's disease, to which ET gets compared to a lot---there's already now so much more known complexity to something that has a very specific idea and concept in people's minds. So, I tend to think we'll still be in an area where we'll have a lot of different causes of tremor, but I'm hopeful that we'll uncover some new mechanisms for which treating or addressing that mechanism would take care of the tremor in a way that we haven't been able to make as much progress on in the last few decades as maybe we would have thought given all the advances in in technology. Dr Jones: That's very helpful, and we'll be hopeful for that series of discoveries that lead us to that point. I think many of our listeners will be familiar with the utility---and, I think, even for most insurance companies, approval---for DAT scans to discriminate between essential tremor and Parkinsonian disorders. What about lab work? Are there any other disorders that you commonly screen for in patients who you suspect may have essential tremor? Dr Shih: Yeah, it's a great question. And I think, you know, I'm always mindful that what I'm seeing in my clinic may not always be representative of what's seen in the community or out in practice. I'll give an example. You know, most of the time when people come to the academic Medical Center, they're thinking, gosh, I've tried this or that. I've been on these medicines for the last ten years. But I've had essential tremor for twenty years. We get to benefit a little bit from all that history that's been laid down. And so, it's not as likely you're going to misdiagnose it. But once in a while, you'll get someone with tremor that just started a month ago or just started, you know, 2 or 3 months ago. And you have to still be thinking, well, I've got to get out of the specialist clinic mindset, and think, well, what else really could this be? And so, while it's true for everybody, moreso in those cases, in those recent onset cases, you really got to be looking for things like medications, electrolyte abnormalities, and new-onset thyroid disorder, for example, thyroid toxicosis. Dr Jones: Very helpful. And your article has a wonderful list of the conditions to consider, including the medications that might be used for those conditions that might result or unmask a tremor of a different cause. And I think being open-minded and not anchoring on essential tremor just because it's common, I think is a is a key point here. And another feature in your article that I really enjoyed was your step-by-step approach to tremor. What are those steps? Dr Shih: Well, I think you know first of all, tremor is such common terminology that even lay people, patients, nonclinicians will use the word “tremor.” And so, it can be tempting when the notes on your schedule says referred for tremor to sort of immediately jump to that. I think the first step is, is it tremor? And that's really something that the clinician first has to decide. And I think that's a really important step. A lot of things can look superficially like tremor, and you shouldn't even assume that another clinician knows what tremor looks like as opposed to, say, myoclonus. Or for example a tremor of the mouth; well, it actually could be orolingual or orobuccal dyskinesia, as in tardive dyskinesia. And another one that tremor can look like is ataxia. And so, I think- while they sound obvious to most neurologists, perhaps, I think that---especially in the area of myoclonus, where it can be quite repetitive, quite small amplitude in some conditions---it can really resemble a tremor. And so, there are examples of these where making that first decision of whether it's a tremor or not can really be a good sort of time-out to make sure you're going down the right path to begin with. And I think what's helpful is to think about some of the clinical definitions of a tremor. And tremor is really rhythmic, it's oscillatory. You should see an agonist and antagonist muscle group moving back and forth, to and fro. And then it's involuntary. And so, I think these descriptors can really help; and to help isolate, if you can describe it in your note, you can probably be more convinced that you're dealing with the tremor. The second step that I would encourage people to really consider: you've established it's a tremor. The most important part exam now becomes, really, the nontremor part of the exam. And it should be really comprehensive to think of what else could be accompanying this, because that's really how we make diagnosis of other things besides essential tremor. There really should be a minimum of evidence of parkinsonism, dystonia, neuropathy, ataxia- and the ataxia could be either from a peripheral or central nervous system etiology. Those are the big four or five things that, you know, I'm very keen to look for and will look pretty much in the head, neck, the axial sort of musculature, as well as the limbs. And I think this is very helpful in terms of identifying cases which turn out to have either, say, well, Parkinson's or even a typical Parkinson disorder; or even a genetic disorder, maybe even something like a fragile X tremor ataxia syndrome; or even a spinal cerebellar ataxia. These cases are rare, but I think if you uncover just enough ataxia, for example, that really shouldn't be there in a person, let's say, who's younger and also doesn't have a long history of tremor; you should be more suspicious that this is not essential tremor that you're dealing with. And then the last thing is, once you've identified the tremor and you're trying to establish, well, what should be done about the tremor, you really have to say what kind of tremor it is so that you can follow it, so you can convey to other people really what the disability is coming from the tremor and how severe the tremor is. So, I think an example of this is, often in the clinic, people will have their patients extend their arms and hands and kind of say, oh, it's an essential tremor, and that's kind of the end of the exam. But it doesn't give you the flavor. Sometimes you'll have a patient come in and have a fairly minimal postural tremor, but then you go out, take those extra few seconds to go grab a cup of water or two cups of water and have them pour or drink. And now all of a sudden you see this tremor is quite large-amplitude and very disabling. Now you have a better appreciation of what you really need to do for this patient, and it might not be present with just these very simple maneuvers that you have at bedside without props and items. And then the severity of it; you know, we're so used to saying mild, moderate, severe. I think what we've done in the Tremor Research Group to use and develop the Essential Tremor Rating Assessment Scale is to get people used to trying to estimate what size the tremor is. And you can do that by taking a ruler or developing a sense of what 1 centimeter, 2 centimeters, 3 centimeters looks like. I think it'd be tremendously helpful too, it's very easy and quick to convey severity in a given patient. Dr Jones: I appreciate you, you know, having a patient-centered approach to the- how this is affecting them and being quantitative in the assessment of the tremor. And that's a great segue to a key question that I run into and I think others run into, which is when to initiate therapy? You know, if you see a patient who, let's say they have a mild tremor or, you know, something that quantitatively is on the mild end of the spectrum, and you have, you know, a series of options… from a medication perspective, you have to say, well, when does this across that threshold of being more likely to benefit the patient than to harm the patient? How do you approach that question? What's your threshold for starting medication? Dr Shih: Yeah. You know, sometimes I will ask, because---and I know this sounds like a strange question---because I feel like my patients will come for a couple of different reasons. Sometimes it's usually one over the other. I think people can get concerned about a symptom of a tremor. So, I actually will ask them, was your goal to just get a sense for what this tremor is caused by? I understand that many people who develop tremor might be concerned it might be something like Parkinson's disease. Or is this also a tremor that is bothering you in day-to-day life? And often you will hear the former. No, I just wanted to get checked out and make sure you don't think it's Parkinson's. It doesn't bother me enough that I want to take medication. They're quite happy with that. And then the second scenario is more the, yeah, no, it bothers me and it's embarrassing. And that's a very common answer you may hear, may be embarrassing, people are noticing. It's funny in that many people with essential tremor don't come to see a doctor or even the neurologist for many years. And they will put up with it for a very long time. And they've adopted all sorts of compensatory strategies, and they've just been able to handle themselves very admirably with this, in some cases, very severe tremor. So, for some of them, it'll take a lot to come to the doctor, and then it becomes clear. They said, I think I'm at the point where I need to do something about this tremor. And so, I think those three buckets are often sort of where my patients fall into. And I think asking them directly will give you a sense of that. But you know, it can be a nice time to try some as-needed doses of something like Propranolol, or if it's something that you know that they're going to need something on day-to-day to get control of the tremor over time, there are other options for that as well. Dr Jones: Seems like a perfect scenario for shared decision-making. Is it bothersome enough to the patient to try the therapy? And I like that suggestion. That's a nice pearl that you could start with an a- needed beta blocker, right, with Propranolol. And this is a question that I think many of us struggle with as well. If you've followed a patient with essential tremor for some time and you've tried different medications and they've either lost effectiveness or have intolerable adverse effects, what is your threshold for referring a patient for at least considering a surgical neurostimulator therapy for their essential tremor? Dr Shih: Yeah, so surgical therapies for tremor have been around for a long time now, since 1997, which was when it was approved by the FDA for essential tremor and Parkinson tremor. And then obviously since then, we have a couple more options in the focus ultrasound thalamotomy, which is a lesioning technique. When you have been on several tremor medications, the list gets smaller and smaller. It- and then chance of likely satisfying benefit from some of these medications can be small and small as you pass through the first and second line agents and these would be the Propranolol and the primidone. And as you say, quite a few patients- it's estimated between 30 to 50% of these patients end up not tolerating these first two medications and end up discontinuing them. Some portion of that might also be due to the fact that some of our patients who have been living with essential tremor for decades now, to the point that their tremor is getting worse, are also getting older. And so, polypharmacy and/or some of the potential side effects of beta blockers and anticonvulsants like primidone may be harder to bear in an older adult. And then as you talk about in the article, there's some level of evidence for topiramate, and then from there a number of anticonvulsants or benzos, which have even weaker evidence for them. It's a personal decision. As I tell folks, look, this is not going to likely extend your life or save your life, but it's a quality of life issue. And of course, if there are other things going on in life that need to be taken care of and they need that kind of care and attention, then, you know, you don't need to be adding this to your plate. But if you are in the position where those other things are actually okay, but quality of life is really affected by your being unable to use your upper limbs in the way that you would like to… A lot of people's hobbies and applications are upper limb-based, and enjoying those things is really important. Then I think that this is something- a conversation that we begin and we begin by talking about yes, there are some risks involved, but fortunately this is the data we have on it, which is a fairly extensive experience in terms of this is the risk of, you know, surgery-related side effects. This is the risk of if you're having stimulation from DBS stimulation-related side effects, which can be adjustable. It's interesting, I was talking with colleagues, you know, after focused ultrasound thalamotomy was approved. That really led more people to come to the clinic and start having these discussions, because that seemed like a very the different sort of approach where hardware wasn't needed, but it was still a surgery. And so, it began that conversation again for a bunch of people to say, you know, what could I do? What could I tolerate? What would I accept in terms of risk and potential benefit? Dr Jones: Well, I think that's a great overview of a disorder where, you know, I think the neurologist's role is really indispensable. Right? I mean, you have to have this conversation not just once, this is a conversation that you have over time. And again, I really want to refer our listeners to this article. It's just a fantastic overview of a common disorder, but one where I think there are probably gaps where we can improve care. And Dr Shih, I want to thank you for joining us, and thank you for such a great discussion on essential tremor. I learned a lot from your article, and I learned even more from the interview today. I suspect our readers and listeners will too. Dr Shih: Well, thank you again for the invitation and the opportunity to kind of spread the word on this really common condition. Dr Jones: Again, we've been speaking with Dr Ludy Shih, author of a fantastic article on essential tremor in Continuum's latest issue on movement disorders. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

DBs coach LaMar Morgan talks fall camp and moreSee omnystudio.com/listener for privacy information.

Chris Stamey in conversation with David Eastaugh https://www.chrisstamey.com/ https://chrisstamey.bandcamp.com/ Anything Is Possible, the latest collection of original material (and one affectionate cover) from North Carolina songwriter / vocalist / guitarist / producer Chris Stamey, an indie rock icon with a long and illustrious history that's encompassed co-founding seminal avant-pop band the dBs, playing with Alex Chilton in the 70s and more recently with Jody Stephens's Big Star Quintet, and recording with the all-star smart-pop outfit the Salt Collective. The new album features special guests such as the Lemon Twigs, Pat Sansone (Wilco), Probyn Gregory (Brian Wilson band), and Marshall Crenshaw among others. The album was produced by Stamey at Modern Recording in Chapel Hill, NC. Anything Is Possible is being released by Label 51 Recordings on 1digital download and streaming platforms today and 12” LP vinyl, CD, August 8.

The range of symptoms and affected body systems in Parkinson's disease is extensive. One area that is less frequently discussed is the vestibular system—the inner ear structure directly connected to the brain, responsible for balance and spatial orientation. When this system malfunctions, individuals may experience dizziness, balance problems and an increased risk of falls, highlighting its importance in your overall health. With aging, the inner ear naturally becomes less robust. Although current research has not yet identified a definitive cause for the higher incidence of vestibular dysfunction in people with Parkinson's disease, effective interventions are available. In this episode, Christopher Taylor, Occupational Therapist at Mayo Clinic, will provide insights into the diagnosis and treatment options—namely vestibular therapy—that can assist with symptoms such as dizziness, gait disturbances, freezing, and postural instability. This discussion aims to enhance our understanding of the crucial role played by the inner ear and its connections. Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches  https://vestibular.org/

Alan Saunders and Zachary Smith discuss all things Pittsburgh Steelers.On today's episode, we discuss Smitty's takeaways from his trip out for Friday Night Lights practice. The DBs continue to stand out in a big way, the approach of the rookie class is something very notable, Broderick Jones isn't answering any questions, Darnell Washington is unbelievable in one on ones and the atmosphere is second to none. We also dive into Alan's updated 53-man roster prediction. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Mitra Afshari interviews Drs. Patricia Krause and Andrea Kühn on the results of a 10-year prospective follow-up study of a multicenter trial of GPI-DBS in isolated generalized and segmental dystonia. Together they discuss motor, non-motor, and safety outcomes, as well as the strong and stable long-term improvements in dystonia from pallidal DBS. Further, they provide their expert insights on the common themes with respect to treatment failure and the critical need for a personalized approach.

As 2025 Chiefs Training Camp rolls on, we sat down and took a look around the league at some active trade requests, Josh Simmons continuing to look like the steal of the draft, the WR battle pretty much locked in, and what will the Chiefs do with all of their DBs?Follow us @KingdomSaysPodlinktr.ee/kingdomsaysSign up to Underdog with our code KINGDOMSAYS to claim your Free Pick + First Time Deposit offer up to $1,000 in bonus cash! ⁠https://play.underdogfantasy.com/p-kingdom-says⁠

Jan, founder of OpenMind, joins Sam to discuss how they're building a memory layer for AI agents in Web3.They cover the limitations of stateless agents, OpenMind's modular memory architecture, and how developers can build “smart, sovereign agents” that persist across time, dApps, and chains. Jan also shares insights on use cases across DeFi, NFTs, and DAOs, and how OpenMind is designing for both developers and end users.If you're exploring the future of AI x Web3, this episode is packed with key insights.Key Timestamps[00:00:00] Introduction: Sam introduces Jan and OpenMind's mission.[00:01:00] Jan's Background: Journey into Web3 and AI, and what led to founding OpenMind.[00:02:30] Problem with Agents Today: Why stateless AI agents don't work long term.[00:04:00] What OpenMind Does: A memory infrastructure layer for AI agents in Web3.[00:05:00] Modular Approach: Indexers, vector DBs, and plug-and-play architecture.[00:06:00] Use Cases: Agents for DeFi, personalized NFT experiences, DAO workflows, and beyond.[00:08:00] Developer Tools: APIs, SDKs, and how to get started building with OpenMind.[00:09:00] Open vs Closed Memory: Why on-chain provenance and user control matter.[00:11:00] Vision for AI Agents: Autonomous, persistent, and identity-aware.[00:13:00] Why Web3 Matters: Data ownership, composability, and aligned incentives.[00:15:00] OpenMind's Ask: Builders, partners, and early adopters — reach out!Connecthttps://openmind.org/https://x.com/openmind_agihttps://www.linkedin.com/company/openmindagi/https://x.com/janliphardthttps://www.linkedin.com/in/jan-liphardt/DisclaimerNothing mentioned in this podcast is investment advice and please do your own research. Finally, it would mean a lot if you can leave a review of this podcast on Apple Podcasts or Spotify and share this podcast with a friend.Be a guest on the podcast or contact us - ⁠https://www.web3pod.xyz/⁠

Looking for an edge in your IDP Drafts? We've got tips to help you draft like an analyst by digging into some readily accessible data for IDP so that you can take an informed approach to determining who is hype and who is the real thing.Hosts Scott Soltis and Jake Kohlhagen share beginner and advanced data points to help you build draft boards that cut through the noise and get to the numbers that matter for IDP in general, defensive line, linebackers, and even DBs. Along the way, the guys illustrate the data with some of the biggest names in IDP as well as lesser-known players who the data suggests should (or shouldn't) be on your radar.Subscribe to our YouTube channel for our other shows, The IDP Show and The IDP After Show.If you'd like to support the show, you can do so for just $5/month over at ⁠theIDPshow.com⁠. We've got some premium features for paid supporters that we know you'll enjoy. Follow us on Twitter ⁠@theidpshow⁠. Thanks for listening!

Alan Saunders and Zachary Smith discuss all things Pittsburgh Steelers. On today's episode, we discuss the DBs bringing the juice to a feisty practice without pads. Juan Thornhill and Jalen Ramsey are known for their trash talk and Thursday was no exception. Thornhill and Jonnu Smith regularly went at it. Aaron Rodgers had a really strong day. Roman Wilson made the play of camp so far, and he will need to show much more of that going forward. How creative will Arthur Smith get, and do we need to adjust the roster math to account for it? Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Michael S. Okun, MD, FAAN, who served as the guest editor of the August 2025 Movement Disorders issue. They provide a preview of the issue, which publishes on August 1, 2025. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Okun is the director at Norman Fixel Institute for Neurological Diseases and distinguished professor of neurology at University of Florida in Gainesville, Florida. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @MichaelOkun Full episode transcript available here: Dr Jones: Our ability to move through the world is one of the essential functions of our nervous system. Gross movements like walking ranging down to fine movements with our eyes and our hands, our ability to create and coordinate movement is something many of us take for granted. So what do we do when those movements stop working as we intend? Today I have the opportunity to speak with one of the world's leading experts on movement disorders, Dr Michael Okun, about the latest issue of Continuum on Movement Disorders. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Michael Okun, who is Continuum's guest editor for our latest issue on movement disorders. Dr Okun is the Adelaide Lackner Distinguished Professor of Neurology at the University of Florida in Gainesville, where he's also the director of the Norman Fixel Institute for Neurological Diseases. Dr Okun, welcome, and thank you for joining us today. Why don't you introduce yourselves to our listeners?  Dr Okun: It's great to be here today. And I'm a neurologist. Everybody who knows me knows I'm pretty simple. I believe the patient's the sun and we should always orbit around the person with disease, and so that's how I look at my practice. And I know we always participate in a lot of research, and I've got a research lab and all those things. But to me, it's always the patients and the families first. So, it'll be great to have that discussion today.  Dr Jones: Yeah, thank you for that, Dr Oaken. Obviously, movement disorders is a huge part of our field of neurology. There are many highly prevalent conditions that fit into this category that most of our listeners will be familiar with: idiopathic Parkinson's disease, essential tremor, tic disorders and so on. And having worked with trainees for a long time, it's one of the areas that I see a lot of trainees gravitate to movement disorders. And I think it's in part because of the prevalence; I think it's in part because of the diversity of the specialty with treatment options and DBS and Botox. But it's also the centrality of the neurologic exam, right? That's- the clinical examination of the patient is so fundamental. And we'll cover a lot of topics today with some questions that I have for you about biomarkers and new developments in the field. But is that your sense too, that people are drawn to just the old-fashioned, essential focus on the neurologic encounter and the neurologic exam? Dr Okun: I believe that is one of the draws to the field of movement. I think that you have neurologists from all over the world that are really interested and fascinated with what things look like. And when you see something that's a little bit, you know, off the normal road or off the normal beaten path… and we are always curious. And so, I got into movement disorders, I think, accidentally; I think even as a child, I was looking at people who had abnormal movements and tremors and I was very fascinated as to why those things happened and what's going on in the brain. And, you know, what are the symptoms and the signs. And then later on, even as my own career developed, that black bag was so great as a neurologist. I mean, it makes us so much more powerful than any of the other clinicians---at least in my biased opinion---out on the wards and out in the clinic. And, you know, knowing the signs and the symptoms, knowing how to do a neurological examination and really walking through the phenomenology, what people look like, you know, which is different than the geno- you know, the genotypes, what the genes are. What people look like is so much more important as clinicians. And so, I think that movement disorders is just the specialty for that, at least in my opinion. Dr Jones: And it helps bring it back to the patient. And that's something that I saw coming through the articles in this issue. And let's get right to it. You've had a chance to review all these articles on all these different topics across the entire field of movement disorders. As you look at that survey of the field, Dr Okun, what do you think is the most exciting recent development for patients with movement disorders?  Dr Okun: I think that when you look across all of the different specialties, what you're seeing is a shift. And the shift is that, you know, a lot of people used to talk in our generation about neurology being one of these “diagnose and adios” specialties. You make the diagnosis and there's nothing that you can do, you know, about these diseases. And boy, that has changed. I mean, we have really blown it out of the water. And when you look at the topics and what people are writing about now and the Continuum issue, and we compare that the last several Continuum issues on movement disorders, we just keep accumulating a knowledge base about what these things look like and how we can treat them. And when we start thinking about, you know, all of the emergence of the autoimmune disorders and identifying the right one and getting something that's quite treatable. Back in my day, and in your day, Lyle, we saw these things and we didn't know what they were. And now we have antibodies, now we can identify them, we can pin them down, and we can treat many of them and really change people's lives. And so, I'm really impressed at what I see in changes in identification of autoimmune disorders, of channelopathies and some of the more rare things, but I'm also impressed with just the fundamental principles of how we're teaching people to be better clinicians in diseases like Parkinson's, Huntington's, ataxia, and Tourette. And so, my enthusiasm for this issue of Continuum is both on, you know, the cutting edge of what we're seeing based on the identification on our exams, what we can do for these people, but also the emergence of how we're shifting and providing much better care across a continuum for folks with basal ganglia diseases. Dr Jones: Yeah, I appreciate that perspective, Dr Okun. One of the common themes that I saw in the issue was with these new developments, right, when you have new tools like new diagnostic biomarker tools, is the question of if and when and how to integrate those into daily clinical practice, right? So, we've had imaging biomarkers for a while, DAT scans, etc. For patients with idiopathic Parkinson disease, one of the things that I hear a lot of discussion and controversy about are the seed amplification assays as diagnostic biomarkers. What can you tell us about those? Are those ready for routine clinical use yet?  Dr Okun: I think the main bottom-line point for folks that are out there trying to practice neurology, either in general clinics or even in specialty clinics, is to know that there is this movement toward, can we biologically classify a disease? One of the things that has, you know, really accelerated that effort has been the development of these seed amplification assays, which---in short for people who are listening---are basically, we “shake and bake” these things. You know? We shake them for like 20 hours and we use these prionlike proteins, and we learn from diseases like prion disease how to kind of tag these things and then see, do they have degenerative properties? And in the case of Parkinson's disease, we're able to do this with synuclein. That is the idea of a seed amplification assay. We're able to use this to see, hey, is there synuclein present or not in this sample? And people are looking at things like cerebrospinal fluid, they're looking at things like blood and saliva, and they're finding it. The challenge here is that, remember- and one of the things that's great about this issue of Continuum is, remember, there are a whole bunch of different synucleinopathies. So, Dr Jones, it isn't just Parkinson's disease. So, you've got Parkinson's disease, you've got Lewy body, you know, and dementia with Lewy bodies. You've got, you know, multiple system atrophy is within that synucleinopathy, you know, group primary autonomic failure… so not just Parkinson's disease. And so, I think we have to tap the brakes as clinicians and just say, we are where we are. We are moving in that direction. And remember that a seed amplification assay gives you some information, but it doesn't give you all the information. It doesn't forgive you looking at a person over time, examining them in your clinic, seeing how they progress, seeing their response to dopamine- and by the way, several of these genes that are associated with Parkinson; and there's, you know, less than 20% of Parkinson is genetic, but several of these genes, in a solid third---and in some cases, in some series, even more---miss the synuclein assay, misses, you know, the presence of a disease like Parkinson's disease. And so, we have to be careful in how we interpret it. And I think we're more likely to see over time a gemish: we're going to smush together all this information. We're going to get better with MRIs. And so, we're actually doing much better with MRIs and AI-based intelligence. We've got DAT scans, we've got synuclein assays. But more than anything, everybody listening out there, you can still examine the person and examine them over time and see how they do over time and see how they do with dopamine. And that is still a really, really solid way to do this. The synuclein assays are probably going to be ready for prime time more in choosing and enriching clinical trials populations first. And you know, we're probably 5, 10 years behind where Alzheimer's is right now. So, we'll get there at some point, but it's not going to be a silver bullet. I think we're looking at these are going to be things that are going to be interpreted in the context for a clinician of our examination and in the context of where the field is and what you're trying to use the information for. Dr Jones: Thank you for that. And I think that's the general gestalt I got from the articles and what I hear from my colleagues. And I think we've seen this in other domains of neurology, right? We have the specificity and sensitivity issues with the biomarkers, but we also have the high prevalence of copathology, right? People can have multiple different neurodegenerative problems, and I think it gets back to that clinical context, like you said, following the patient longitudinally. That was a theme that came out in the idiopathic Parkinson disease article. And while we're on Parkinson disease, you know, the first description of that was what, more than two hundred years ago. And I think we're still thinking about the pathophysiology of that disorder. We understand risk factors, and I think many of our listeners would be familiar with those. But as far as the actual cause, you know, there's been discussion in recent years about, is there a role of the gut microbiome? Is this a prionopathic disorder? What's your take on all of that?  Dr Okun: Yeah, so it's a great question. It's a super-hot area right now of Parkinson. And I kind of take this, you know, apart in a couple of different ways. First of all, when we think about Parkinson disease, we have to think upstream. Like, what are the cause and causes? Okay? So, Parkinson is not one disease, okay? And even within the genes, there's a bunch of different genes that cause it. But then we have to look and say, well, if that's less than 20% depending on who's counting, then 80% don't have a single piece of DNA that's closely associated with this syndrome. And so, what are we missing with environment and other factors? We need to understand not what happens at the end of the process, not necessarily when synuclein is clumping- and by the way, there's a lot of synuclein in the brains normally, and there's a lot of Tau in people's brains who have Parkinson as well. We don't know what we don't know, Dr Jones. And so when we begin to think about this disease, we've got to look upstream. We've got to start to think, where do things really start? Okay? We've got to stop looking at it as probably a single disease or disorder, and it's a circuit disorder. And then as we begin to develop and follow people along that pathway and continuum, we're going to realize that it's not a one-size-fits-all equation when we're trying to look at Parkinson. By the way, for people listening, we only spend two to three cents out of every dollar on prevention. Wouldn't prevention be the best cure, right? Like, if we were thinking about this disease. And so that's something that we should be, you know, thinking about. And then the other is the Global Burden of Disease study. You know, when we wrote about this in a book called Ending Parkinson's Disease, it looked like Parkinson's was going to double by 2035. The new numbers tell us it's almost double to the level that we expected in 2035 in this last series of numbers. So, it's actually growing much faster. We have to ask why? Why is it growing faster? And then we have lots of folks, and even within these issues here within Continuum, people are beginning to talk about maybe these environmental things that might be blind spots. Is it starting in our nose? Is it starting in our gut? And then we get to the gut question. And the gut question is, if we look at the microbiomes of people with Parkinson, there does seem to be, in a group of folks with Parkinson, a Parkinson microbiome. Not in everyone, but if you look at it in composite, there seems to be some clues there. We see changes in Lactobacillus, we see some bacteria going up that are good, some bacteria going down, you know, that are bad. And we see flipping around, and that can change as we put people on probiotics and we try to do fecal microbiota transplantations- which, by the way, the data so far has not been positive in Parkinson's. Doesn't mean we might not get there at some point, but I think the main point here is that as we move into the AI generation, there are just millions and millions and millions of organisms within your gut. And it's going to take more than just our eyes and just our regular arithmetic. You and I probably know how to do arithmetic really well, but this is, like, going to be a much bigger problem for computers that are way smarter than our brains to start to look and say, well, we see the bacteria is up here. That's a good bacteria, that's a good thing or it's down with this bacteria or this phage or there's a relationship or proportion that's changing. And so, we're not quite there. And so, I always tell people---and you know, we talk about the sum in the issue---microbiomes aren't quite ready for prime time yet. And so be careful, because you could tweak the system and you might actually end up worse than before you started. So, we don't know what we don't know on this issue.  Dr Jones: And that's a great point. And one of the themes they're reading between the lines is, we will continue to work on understanding the bio-pathophysiology, but we can't wait until that day to start managing the risk factors and treating patients, which I think is a good point. And if we pivot to treatment here a little bit, you know, one of the exciting areas of movement disorders---and really neurology broadly, I think movement disorders has led the field in many ways---is bioelectronic therapy, or what one of my colleagues taught me is “electroceutical therapy”, which I think is a wonderful term. Dr Okun, when our listeners are hearing about the latest in deep brain stimulation in patients who have movement disorders, what should they know? What are the latest developments in that area with devices? Dr Okun: Yeah. So, they should know that things are moving rapidly in the field of putting electricity into the brain. And we're way past the era where we thought putting a little bit of electricity was snake oil. We know we can actually drive these circuits, and we know that many of these disorders---and actually, probably all of the disorders within this issue of Continuum---are all circuit disorders. And so, you can drive the circuit by modulating the circuit. And it's turned out to be quite robust with therapies like deep brain stimulation. Now, we're seeing uses of deep brain stimulation across multiple of these disorders now. So, for example, you may think of it in Parkinson's disease, but now we're also seeing people use it to help in cases where you need to palliate very severe and bothersome chorea and Huntington's disease, we're seeing it move along in Tourette syndrome. We of course have seen this for various hyperkinetic disorders and dystonias. And so, the main thing for clinicians to realize when dealing with neuromodulation is, take a deep breath because it can be overwhelming. We have a lot of different devices in the marketplace and no matter how many different devices we have in the marketplace, the most important thing is that we get the leads. You know, where we're stimulating into the right location. It's like real estate: location, location, location, whether you've got a lead that can steer left, right, up, down and do all of these things. Second, if you're feeling overwhelmed because there are so many devices and so many settings, especially as we put these leads in and they have all sorts of different, you know, nodes on them and you can steer this way and that way, you are not alone. Everybody is feeling that way now. And we're beginning to see AI solutions to that that are going to merge together with imaging, and then we're moving toward an era of, you know, should I say things like robotic programming, where it's going to be actually so complicated as we move forward that we're going to have to automate these systems. There's no way to get this and scale this for all of the locales within the United States, but within the entire world of people that need these types of devices and these therapies. And so, it's moving rapidly. It's overwhelming. The most important thing is choosing the right person. Okay? For this, with multidisciplinary teams, getting the lead in the right place. And then all these other little bells and whistles, they're like sculpting. So, if you think of a sculpture, you kind of get that sculpture almost there. You know, those little adds are helping to maybe make the eyes come out a little more or the facial expression a little bit better. There's little bits of sculpting. But if you're feeling overwhelmed by it, everybody is. And then also remember that we're starting to move towards some trials here that are in their early stages. And a lot of times when we start, we need more failures to get to our successes. So, we're seeing trials of people looking at, like, oligo therapies and protein therapies. We're seeing CRISPR gene therapies in the laboratory. And we should have a zero tolerance for errors with CRISPR, okay? we still have issues with CRISPR in the laboratory and which ones we apply it to and with animals. But it's still pretty exciting when we're starting to see some of these therapies move forward. We're going to see gene therapies, and then the other thing we're going to see are nano-therapies. And remember, smaller can be better. It can slip across the blood brain barrier, you have very good surface area-to-volume ratios, and we can uncage drugs by shining things like focused ultrasound beams or magnets or heat onto these particles to turn them on or off. And so, we're seeing a great change in the field there. And then also, I should mention: pumps are coming and they're here. We're getting pumps like we have for diabetes and neurology. It's very exciting. It's going to be overwhelming as everybody tries to learn how to do this. So again, if you're feeling overwhelmed, so am I. Okay? But you know, pumps underneath the skin for dopamine, pumps underneath the skin for apomorphine. And that may apply to other disorders and not just Parkinson as we move along, what we put into those therapies. So, we're seeing that age come forward. And then making lesions from outside the brain with focused ultrasound, we're starting to get better at that. Precision is less coming from outside the brain; complications are also less. And as we learn how to do that better, that also can provide more options for folks. So, a lot of things to read about in this issue of Continuum and a lot of really interesting and beyond, I would say, you know, the horizon as to where we're headed.  Dr Jones: Thank you for that. And it is a lot. It can be overwhelming, which I guess is maybe a good reason to read the issue, right? I think that's a great place to end and encourage our listeners to pick up the issue. And Dr Okun, I want to thank you for joining us today. Thank you for such a great discussion on movement disorders. I learned a lot. I'm sure our listeners will as well, given the importance of the topic, your leadership in the field over many years. I'm grateful that you have put this issue together. So, thank you. And you're a busy person. I don't know how we talked you into doing this, but I'm really glad that we did.  Dr Okun: Well, it's been my honor. And I just want to point out that the whole authorship panel that agreed to write these articles, they did all the work. I'm just a talking head here, you know, telling you what they did, but they're writing, and the people that are in the field are really, you know, leading and helping us to understand, and have really put it together in a way that's kind of helped us to be better clinicians and to impact more lives. So, I want to thank the group of authors, and thank you, Dr Jones. Dr Jones: Again, we've been speaking with Dr Michael Okun, guest editor of Continuum's most recent issue on movement disorders. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

"Deepest. Bluest. My hat is like a shark's fin." - Henry David Thoreau This week, we're visiting the Aquatica Research Facility and submerging ourselves in the 1999 sci-fi/action/thriller Deep Blue Sea. Originally conceived as Jurassic Park meets Jaws, the filmmakers ultimately decided to take a page from Alien's playbook instead. Join us as we discuss the pros and cons of that approach, compare the finished film with earlier iterations of the script, go over our favorite characters and set pieces, dissect the lyrics of LL Cool J's tie-in song,  try to make sense of the two straight-to-video sequels, and contemplate DBS's place in the pantheon of non-Jaws shark movies. Apple Podcasts | Spotify | Facebook | Instagram Chris's Instagram | Kristen's Instagram Chris & Kristen's Web Series: The Strange Case of Lucy Chandler

One of the possibilities along the Parkinson's journey is losing the ability to drive safely. This possibility is a scary one. For many, driving equals independence. So, it means more than just the hassle of getting around. It means losing your independence. It can lead to depression and anxiety. However, it is important to be safe on the road while driving a multi-ton vehicle. We must protect ourselves, our family, and others on the road. So, we are talking today with an Occupational Therapist who is so passionate about this topic that she started a business focused on helping people keep their independence if possible. She will take us through the when, why, how of driving while diagnosed with Parkinson's. OTs are the professionals trained to assess patients on activities of daily living which includes testing people on their driving skills. We discuss the testing process and the legal implications. There are many options for people once it is determined there is a driving defiicit. So, don't give up. Ask an Occupational Therapist for suggestions.  Listen in to learn everything about driving with PD. https://drivingtoindependence.com/ https://www.aded.net/? https://www.dbsandme.com/17branches Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

It's another rock bottom for the Pirates after being swept by the White Sox. Can you trust Cherington to handle the deadline? We're on Ben Cherington watch today. His contract could keep him around longer though. We react to Kevin Gorman's comments on the topics. Callers give their thought, including one who still will go to games regardless. More callers are eager to give their take on the Pirates, some are ready for Steelers season. The Steelers announced their throwback jerseys from 33. Another caller is worried about Rodgers staying healthy. Another caller is defending Bob Nutting. Others bring up the missed opportunities to add to the roster recently. Noah Hiles joins to discuss how the Pirates are feeling after the awful week, Ben Cherington's job security, can he successfully navigate the trade deadline, what type of players the Pirates could target at the deadline, could Cutch get dealt. Will Keller's value be at its highest now or in the offseason? It's almost time for Steelers training camp. Their spending on defense is in contrast to most of the NFL. A caller throws shade at Callas but he had an epic wiffleball call over the weekend. TJ Watt is 9 spots below Garrett on PFF's top 50, could the Packers be a trade partner for the Steelers at WR. Nick Farabaugh joins to discuss his take on the Steelers new throwback uniforms, what questions he wants answers at training camp, Watt's usage, which young player needs to have a big year, what will be the biggest overreactions in training camp, how bad is Juan Thornhill, which DBs could see extensive snaps, who could be next for an extension. The Sean Segment - Acuna's throw, WNBA players want better pay, Rich Hill is still going, McDavid plays beer league hockey, Erie's minor league baseball team is rebranded. ESPN ranked the best NFL rosters, and the Steelers are surprisingly low. We react to their supposed weaknesses, strengths, and X factors. What are the biggest storylines for Steelers camp - Broderick Jones, Kaleb Johnson, will there be additions at WR/safety, Jalen Ramsey's position. Johnny the Barber challenges Bechtold. Austin went to the Pirates game on Saturday and was mad about the people just there to sell their bobbleheads.

DBs from SE MichiganSee omnystudio.com/listener for privacy information.

Experts not high on the 2025 DBs in DC

7.10.25 What are the next steps when it comes to improving the DBs? Projections for Deatrich Wise Jr. in 2025